Five US-listed Dividend Kings—Johnson & Johnson, Procter & Gamble, Coca-Cola, Colgate-Palmolive, and Lowe's—have announced dividend increases and reported earnings reflecting resilience amid economic challenges like tariffs and currency swings. Johnson & Johnson raised dividends by 3.1% with strong revenue growth, while Procter & Gamble marked its 70th consecutive dividend hike despite some revenue misses. Coca-Cola showed standout growth with a raised outlook, Colgate-Palmolive benefited from pricing power, and Lowe's, despite a slight earnings miss, remains a long-term buy with a recent dividend increase. Investors should watch Lowe's upcoming earnings closely due to housing market concerns.
Johnson & Johnson is rated HOLD for the next 6-12 months due to balanced risks. Its drug portfolio growth offsets losses from Stelara, but the MedTech segment remains a weak growth driver. The company's valuation is above historical averages, reflect...
Procter & Gamble (P&G) and Johnson & Johnson (J&J) both recently increased their long-standing dividends, but P&G's dividend appears more stable due to no planned corporate changes. J&J is preparing a mid-2027 spinoff of its DePuy Synthes unit, which...
JPMorgan's JEPI ETF has seen its monthly payouts decrease throughout 2026 despite the S&P 500 rallying strongly. JEPI's strategy of selling option premiums on low-volatility stocks limits upside gains, making it underperform in a calm, rising market....
The Health Care Select Sector SPDR Fund (XLV) offers broad healthcare exposure but delivers a low dividend yield around 1.5% due to its cap-weighted structure favoring large, lower-yield stocks like Eli Lilly. Directly owning top XLV holdings AbbVie,...
Despite two major recessions in the past two decades, four healthcare companies—Johnson & Johnson, Abbott Laboratories, Medtronic, and Becton Dickinson—consistently raised their dividends each quarter. Their strong cash flows and inelastic demand for...
